Septa Pharmaceuticals Acquires CeeNU® from Bristol Myers Squibb

Septa Pharmaceuticals Inc., a growing force in Canada's healthcare industry, has successfully acquired CeeNU® (Lomustine) from Bristol Myers Squibb, Canada. This acquisition, finalized on June 29, 2026, marks a significant expansion for Septa, reinforcing its focus on oncology. CeeNU®, an established chemotherapy drug, is primarily used to treat certain brain tumors and Hodgkin's lymphoma.

Septa is dedicated to maintaining continuous patient access to CeeNU® across Canada. The company emphasizes the importance of a stable supply of critical medications in the complex healthcare landscape. As part of this integration, Septa plans to work with stakeholders to ensure a seamless transition.

Looking ahead, Septa is seeking new partnerships to commercialize high-impact therapies globally, aiming for mutual growth and broader market reach for its pharmaceutical products.